BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 27774565)

  • 1. The time to and determinants of first fractures in boys with Duchenne muscular dystrophy.
    Ma J; McMillan HJ; Karagüzel G; Goodin C; Wasson J; Matzinger MA; DesClouds P; Cram D; Page M; Konji VN; Lentle B; Ward LM
    Osteoporos Int; 2017 Feb; 28(2):597-608. PubMed ID: 27774565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors associated with prevalent vertebral fractures in Duchenne muscular dystrophy.
    Phung K; McAdam L; Ma J; McMillan HJ; Jackowski S; Scharke M; Matzinger MA; Shenouda N; Koujok K; Jaremko JL; Smit K; Walker S; Hartigan C; Khan N; Konji VN; MacLeay L; Page M; Sykes E; Robinson ME; Alos N; Cummings EA; Ho J; Sbrocchi AM; Stein R; Saleh D; Craven BC; Dang UJ; Siminoski K; Rauch F; Ward LM
    Osteoporos Int; 2023 Jan; 34(1):147-160. PubMed ID: 36342539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk Factors Associated with Incident Vertebral Fractures in Steroid-treated Males with Duchenne Muscular Dystrophy.
    Phung K; McAdam L; Ma J; McMillan HJ; Jackowski S; Scharke M; Matzinger MA; Shenouda N; Koujok K; Jaremko JL; Wilson N; Walker S; Hartigan C; Khan N; Page M; Robinson ME; Saleh DS; Smit K; Rauch F; Siminoski K; Ward LM
    J Clin Endocrinol Metab; 2024 Jan; 109(2):536-548. PubMed ID: 37610420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy.
    Sbrocchi AM; Rauch F; Jacob P; McCormick A; McMillan HJ; Matzinger MA; Ward LM
    Osteoporos Int; 2012 Nov; 23(11):2703-11. PubMed ID: 22297733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.
    Tian C; Wong BL; Hornung L; Khoury JC; Miller L; Bange J; Rybalsky I; Rutter MM
    Neuromuscul Disord; 2016 Nov; 26(11):760-767. PubMed ID: 27614576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different bone health progression patterns and early-stage risk marker in glucocorticoid-treated ambulatory Duchenne muscular dystrophy.
    Zhou L; Zhou H; Xu H; Sun X; Chen X; Fan P; Cai X; Wang Q
    Osteoporos Int; 2024 Jun; 35(6):997-1005. PubMed ID: 38277031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth, bone health & ambulatory status of boys with DMD treated with daily vs. intermittent oral glucocorticoid regimen.
    Crabtree NJ; Adams JE; Padidela R; Shaw NJ; Högler W; Roper H; Hughes I; Daniel A; Mughal MZ
    Bone; 2018 Nov; 116():181-186. PubMed ID: 30055340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vertebral Fractures in Duchenne Muscular Dystrophy Patients Managed With Deflazacort.
    Singh A; Schaeffer EK; Reilly CW
    J Pediatr Orthop; 2018 Jul; 38(6):320-324. PubMed ID: 27328118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fractures and Linear Growth in a Nationwide Cohort of Boys With Duchenne Muscular Dystrophy With and Without Glucocorticoid Treatment: Results From the UK NorthStar Database.
    Joseph S; Wang C; Bushby K; Guglieri M; Horrocks I; Straub V; Ahmed SF; Wong SC;
    JAMA Neurol; 2019 Jun; 76(6):701-709. PubMed ID: 30855644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoporotic Fractures and Vertebral Body Reshaping in Children With Glucocorticoid-treated Rheumatic Disorders.
    Ward LM; Ma J; Robinson ME; Scharke M; Ho J; Houghton K; Huber A; Scuccimarri R; Barsalou J; Roth J; Shenouda N; Matzinger MA; Lentle B; Jaremko JL; Koujok K; Watanabe Duffy K; Stein R; Sbrocchi AM; Rodd C; Miettunen PM; LeBlanc CMA; Larche M; Jurencak R; Cummings EA; Couch R; Cabral DA; Atkinson S; Alos N; Sykes E; Konji VN; Rauch F; Siminoski K; Lang B
    J Clin Endocrinol Metab; 2021 Nov; 106(12):e5195-e5207. PubMed ID: 34232311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The associations between QCT-based vertebral bone measurements and prevalent vertebral fractures depend on the spinal locations of both bone measurement and fracture.
    Anderson DE; Demissie S; Allaire BT; Bruno AG; Kopperdahl DL; Keaveny TM; Kiel DP; Bouxsein ML
    Osteoporos Int; 2014 Feb; 25(2):559-66. PubMed ID: 23925651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone density and bone health alteration in boys with Duchenne Muscular Dystrophy: a prospective observational study.
    Suthar R; Reddy BVC; Malviya M; Sirari T; Attri SV; Patial A; Tageja M; Didwal G; Khandelwal NK; Saini AG; Saini L; Sahu JK; Dayal D; Sankhyan N
    J Pediatr Endocrinol Metab; 2021 May; 34(5):573-581. PubMed ID: 33838091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis of vertebral fractures using a low-dose biplanar imaging system.
    Briot K; Fechtenbaum J; Etcheto A; Kolta S; Feydy A; Roux C
    Osteoporos Int; 2015 Nov; 26(11):2649-55. PubMed ID: 26048676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skeletal findings in the first 12 months following initiation of glucocorticoid therapy for pediatric nephrotic syndrome.
    Phan V; Blydt-Hansen T; Feber J; Alos N; Arora S; Atkinson S; Bell L; Clarson C; Couch R; Cummings EA; Filler G; Grant RM; Grimmer J; Hebert D; Lentle B; Ma J; Matzinger M; Midgley J; Pinsk M; Rodd C; Shenouda N; Stein R; Stephure D; Taback S; Williams K; Rauch F; Siminoski K; Ward LM;
    Osteoporos Int; 2014 Feb; 25(2):627-37. PubMed ID: 23948876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone Morbidity and Recovery in Children With Acute Lymphoblastic Leukemia: Results of a Six-Year Prospective Cohort Study.
    Ward LM; Ma J; Lang B; Ho J; Alos N; Matzinger MA; Shenouda N; Lentle B; Jaremko JL; Wilson B; Stephure D; Stein R; Sbrocchi AM; Rodd C; Lewis V; Israels S; Grant RM; Fernandez CV; Dix DB; Cummings EA; Couch R; Cairney E; Barr R; Abish S; Atkinson SA; Hay J; Rauch F; Moher D; Siminoski K; Halton J;
    J Bone Miner Res; 2018 Aug; 33(8):1435-1443. PubMed ID: 29786884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy.
    Tian C; Wong BL; Hornung L; Khoury JC; Rybalsky I; Shellenbarger KC; Rutter MM
    Neuromuscul Disord; 2020 Jul; 30(7):599-610. PubMed ID: 32680651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fractures and bone health monitoring in boys with Duchenne muscular dystrophy managed within the Scottish Muscle Network.
    Joseph S; Wang C; Di Marco M; Horrocks I; Abu-Arafeh I; Baxter A; Cordeiro N; McLellan L; McWilliam K; Naismith K; Stephen E; Ahmed SF; Wong SC
    Neuromuscul Disord; 2019 Jan; 29(1):59-66. PubMed ID: 30473133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skeletal findings in children recently initiating glucocorticoids for the treatment of nephrotic syndrome.
    Feber J; Gaboury I; Ni A; Alos N; Arora S; Bell L; Blydt-Hansen T; Clarson C; Filler G; Hay J; Hebert D; Lentle B; Matzinger M; Midgley J; Moher D; Pinsk M; Rauch F; Rodd C; Shenouda N; Siminoski K; Ward LM;
    Osteoporos Int; 2012 Feb; 23(2):751-60. PubMed ID: 21494860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone mineral density and fractures in boys with Duchenne muscular dystrophy.
    Larson CM; Henderson RC
    J Pediatr Orthop; 2000; 20(1):71-4. PubMed ID: 10641693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of oral bisphosphonate therapy on vertebral morphometry and fractures in patients with Duchenne muscular dystrophy and glucocorticoid-induced osteoporosis.
    Nasomyont N; Tian C; Hornung L; Khoury J; Hochwalt PM; Tilden JC; Wong BL; Rutter MM
    Muscle Nerve; 2021 Dec; 64(6):710-716. PubMed ID: 34506040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.